Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1.

Literature DB >> 8327516

A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1.

M Yu¹, J Ojwang, O Yamada, A Hampel, J Rapapport, D Looney, F Wong-Staal.

Abstract

Ribozymes have enormous potential as antiviral agents. We have previously reported that a hairpin ribozyme expressed under the control of the beta-actin promoter that cleaves human immunodeficiency virus type 1 (HIV-1) RNA in the leader sequence can inhibit HIV-1 (pHXB2gpt) expression. For such a ribozyme in a retroviral vector delivery system to be useful in gene therapy for the treatment of HIV-1 infection, it must be able to inhibit the expression of multiple HIV-1 strains. We have now cloned this ribozyme into various regular expression vectors (including retroviral vectors) by using various gene expression control strategies. Here we show by transient transfection that inhibition of expression of diverse strains of HIV-1 can be achieved by this ribozyme expressed in the proper vectors. These data further support the potential of this hairpin ribozyme as a therapeutic agent for HIV-1.

Entities: Disease Species

Mesh：

Substances：

Year: 1993 PMID： 8327516 PMCID： PMC46924 DOI： 10.1073/pnas.90.13.6340

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

15 in total

1. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication.

Authors: B A Sullenger; H F Gallardo; G E Ungers; E Gilboa
Journal: Cell Date: 1990-11-02 Impact factor: 41.582

2. Ribozymes as potential anti-HIV-1 therapeutic agents.

Authors: N Sarver; E M Cantin; P S Chang; J A Zaia; P A Ladne; D A Stephens; J J Rossi
Journal: Science Date: 1990-03-09 Impact factor: 47.728

3. Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates.

Authors: S Joseph; A Berzal-Herranz; B M Chowrira; S E Butcher; J M Burke
Journal: Genes Dev Date: 1993-01 Impact factor: 11.361

4. RNA catalytic properties of the minimum (-)sTRSV sequence.

Authors: A Hampel; R Tritz
Journal: Biochemistry Date: 1989-06-13 Impact factor: 3.162

5. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication.

Authors: B A Sullenger; T C Lee; C A Smith; G E Ungers; E Gilboa
Journal: Mol Cell Biol Date: 1990-12 Impact factor: 4.272

6. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme.

Authors: M Weerasinghe; S E Liem; S Asad; S E Read; S Joshi
Journal: J Virol Date: 1991-10 Impact factor: 5.103

7. Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression.

Authors: B Dropulić; N H Lin; M A Martin; K T Jeang
Journal: J Virol Date: 1992-03 Impact factor: 5.103

8. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme.

Authors: J O Ojwang; A Hampel; D J Looney; F Wong-Staal; J Rappaport
Journal: Proc Natl Acad Sci U S A Date: 1992-11-15 Impact factor: 11.205

9. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

Authors: S K Arya; C Guo; S F Josephs; F Wong-Staal
Journal: Science Date: 1985-07-05 Impact factor: 47.728

10. Ribozyme mediated destruction of RNA in vivo.

Authors: M Cotten; M L Birnstiel
Journal: EMBO J Date: 1989-12-01 Impact factor: 11.598

60 in total

1. UV cross-link mapping of the substrate-binding site of an RNase P ribozyme to a target mRNA sequence.

Authors: A F Kilani; F Liu
Journal: RNA Date: 1999-09 Impact factor: 4.942

2. Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells.

Authors: T Kuwabara; M Warashina; S Koseki; M Sano; J Ohkawa; K Nakayama; K Taira
Journal: Nucleic Acids Res Date: 2001-07-01 Impact factor: 16.971

10. Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle.

Authors: F Shaheen; L Duan; M Zhu; O Bagasra; R J Pomerantz
Journal: J Virol Date: 1996-06 Impact factor: 5.103

A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1.

1. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication.

2. Ribozymes as potential anti-HIV-1 therapeutic agents.

3. Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates.

4. RNA catalytic properties of the minimum (-)sTRSV sequence.

5. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication.

6. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme.

7. Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression.

8. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme.

9. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

10. Ribozyme mediated destruction of RNA in vivo.

1. UV cross-link mapping of the substrate-binding site of an RNase P ribozyme to a target mRNA sequence.

2. Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells.

Review 3. The hairpin ribozyme. Discovery, mechanism, and development for gene therapy.

4. Promoter choice affects the potency of HIV-1 specific RNA interference.

5. Efficient and specific ribozyme-mediated reduction of bovine alpha-lactalbumin expression in double transgenic mice.

6. Artificial regulation of gene expression in Escherichia coli by RNase P.

7. Ribozyme mediated degradation of beta-amyloid peptide precursor mRNA in COS-7 cells.

8. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.

9. A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection.

10. Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle.